Search hospitals > Minnesota > Duluth

CCOP - Duluth

Claim this profile
Duluth, Minnesota 55805
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Lymphoma
Conducts research for Colorectal Cancer
246 reported clinical trials
10 medical researchers
Photo of CCOP - Duluth in DuluthPhoto of CCOP - Duluth in Duluth

Summary

CCOP - Duluth is a medical facility located in Duluth, Minnesota. This center is recognized for care of Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Lymphoma, Colorectal Cancer and other specialties. CCOP - Duluth is involved with conducting 246 clinical trials across 178 conditions. There are 10 research doctors associated with this hospital, such as Rodolfo E. Bordoni, Amelia B Zelnak, MD, Sreekanth C. Reddy, and Gena H. Volas-Redd.

Area of expertise

1Breast Cancer
Global Leader
CCOP - Duluth has run 68 trials for Breast Cancer. Some of their research focus areas include:
HER2 positive
ER positive
HER2 negative
2Lung Cancer
Global Leader
CCOP - Duluth has run 52 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II

Top PIs

Rodolfo E. BordoniNorthside Hospital3 years of reported clinical research
Studies Lung Cancer
Studies Thyroid Cancer
15 reported clinical trials
30 drugs studied
Amelia B Zelnak, MDNorthside Hospital1 year of reported clinical research
Expert in Breast Cancer
Studies Breast cancer
14 reported clinical trials
52 drugs studied
Sreekanth C. ReddyNorthside Hospital5 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
7 reported clinical trials
15 drugs studied
Gena H. Volas-ReddNorthside Hospital2 years of reported clinical research
Studies Thyroid Cancer
Studies Glioblastoma
6 reported clinical trials
13 drugs studied

Clinical Trials running at CCOP - Duluth

Breast Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Cutaneous Melanoma
Skin Cancer
Breast cancer
Thyroid Cancer
Melanoma
Bladder Cancer
ALK Gene Rearrangement
Image of trial facility.

Chemotherapy + Hormone Therapy

for Breast Cancer

This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Image of trial facility.

Pembrolizumab

for Triple-Negative Breast Cancer

The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Image of trial facility.

T-DM1 + Tucatinib

for Breast Cancer

This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria

Similar Hospitals nearby

Select from list below to view details

Frequently asked questions

What kind of research happens at CCOP - Duluth?
CCOP - Duluth is a medical facility located in Duluth, Minnesota. This center is recognized for care of Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Lymphoma, Colorectal Cancer and other specialties. CCOP - Duluth is involved with conducting 246 clinical trials across 178 conditions. There are 10 research doctors associated with this hospital, such as Rodolfo E. Bordoni, Amelia B Zelnak, MD, Sreekanth C. Reddy, and Gena H. Volas-Redd.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top